History and clinical features at presentation (total eyes: n=40)
| Risk factors | Number of patients (%) |
| Prior vegetative trauma | 12 (30.0%) |
| Corneal transplantation | 7 (17.5%) |
| Associated systemic comorbidities | |
| Postrenal transplantation | 1 (2.5%) |
| Chemotherapy for renal carcinoma | 1 (2.5%) |
| Vitamin A deficiency | 2 (5.0%) |
| Other systemic diseases | 3 (7.5%) |
| Poor ocular surface | |
| Post-Steven-Johnson syndrome | 1 (2.5%) |
| Postchemical injury | 2 (5.0%) |
| Decompensated cornea | 1 (2.5%) |
| Previous history of ocular surgery | |
| Paediatric lens aspiration | 1 (2.5%) |
| Postcorneal tear repair | 1 (2.5%) |
| Nasolacrimal duct obstruction | 1 (2.5%) |
| Total | 33 (82.5%) |
| Prior topical medication | |
| Steroids | 7 (17.5%) |
| Antibiotics | 3 (7.5%) |
| Gatifloxacin 0.3% | 1 (2.5%) |
| Ofloxacin 0.3% | 2 (5.0%) |
| Moxifloxacin 0.5% | 1 (2.5%) |
| Moxifloxacin 0.5% + tobramycin 0.3% | 5 (12.5%) |
| Antifungal (natamycin 5%) | 7 (17.5%) |
| Combination of topical antibiotics (gatifloxacin 0.3%: n=2; moxifloxacin 0.5%: n=5) and antifungal | 8 (20.0%) |
| Cocktail of various topical medications (antibiotics, antifungal, antivirals, lubricants) | 8 (20.0%) |
| Total | 34 (85.0%) |
| Clinical features | |
| Mean duration of symptoms (days) | 20.2±18.6* |
| Best-corrected visual acuity | |
| ≥20/200 | 9 (22.5 %) |
| CF | 8 (20.0%) |
| HM+ | 15 (37.5%) |
| PL+PR inaccurate | 8 (20.0%) |
| Size of the infiltrate | |
| Small (<6 mm) | 22 (55.0%) |
| Large (>6 mm) | 18 (45.0%) |
| Depth of the infiltrate | |
| Superficial stromal | 11 (27.5%) |
| Mid stromal | 9 (22.5%) |
| Deep stromal | 15 (37.5%) |
| >60% thinning | 6 (15.0%) |
| Perforated | 5 (12.5%) |
| Hypopyon | |
| Absent | 20 (50.0%) |
| <4 mm | 10 (25.0%) |
| >4 mm | 3 (7.5%) |
| Could not be ascertained (near total/total infiltrate) | 7 (17.5%) |
*Range: 1–75 days; median: 14 days.